BrePco Biopharma and Piramal Critical Care announce MHRA approval for Neoatricon in UK
PCC has secured the commercialization rights for the EU, UK, and Norway and will be responsible for distributing Neoatricon in these regions
PCC has secured the commercialization rights for the EU, UK, and Norway and will be responsible for distributing Neoatricon in these regions
This approval has come from the company's finished dosage form manufacturing facility
The product will be manufactured at the plant of Bell, Sons & Co. (Druggists) Ltd. located at Gifford House, Slaidburn Crescent, Southport, UK
Lutio has the potential to offer significant cost savings when available to UK patients.
Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Talicia is also approved and launched in the UAE and additional countries may accept UK MHRA approvals as a reference for their own marketing approval processes
NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
Subscribe To Our Newsletter & Stay Updated